ClinicalTrials.gg
RecruitingNCT05742607Updated Jun 17, 2026

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

A Phase 2 interventional study of IPH5201 + durvalumab + standard chemotherapy in Non Small Cell Lung Cancer, sponsored by Innate Pharma. Recruiting at 30 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Innate Pharma · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
48th of 94
70 · median 74
Started
2023
with 2 others
Phase 2
58 of 94
11 open now
Primary completion
2027-06
later than 27 of 36 live
Registered
81st of 94
by date

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 48th largest by planned enrollment, is one of 3 that started in 2023, is one of 58 in phase 2, reaches primary completion later than 27 of the 36 other live ones, and was the 81st registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

In Cohort 1, the study was intended to assess safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab, in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC).

Study Design was updated following the results of interim analysis # 2 (protocol amendment, adding cohort 2).

Cohort 2 includes patients with resectable Stage II to IIIB NSCLC expressing PD-L1 ≥1%, receiving (only) neoadjuvant IPH5201+ durvalumab + chemotherapy

Read the detailed description

Currently enrolling in Cohort 2: this is an open-label, single-arm multicenter study. Eligible NSCLC patients PD-L1 ≥1% will be enrolled and will receive IPH5201 + Durvalumab + standard of care chemotherapy before surgery.

03

Conditions studied

  • Non Small Cell Lung Cancer

Keywords

  • NSCL
  • neoadjuvant
  • adjuvant
  • perioperative
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients are eligible to be included in the study only if all of the following criteria apply:

  1. Capable of giving signed , which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol.
  2. Provision of signed and dated written ICF prior to any mandatory study specific procedures, sampling, and analyses - including collection of samples for genetic analysis, if applicable.
  3. Patients must be ≥18 years at the time of screening.
  4. Newly diagnosed and previously untreated patients with or cytologically documented NSCLC. Patients should have resectable disease (Stage IIA to Stage IIIA; Stage IIIB - Nodal stage N2 after the first 40 patients [cohort 2]), according to Version 8 of IASLC Staging Manual in Thoracic Oncology (2016), and be candidates for lobectomy, sleeve resection, or bilobectomy at the time of screening. For patients with N2 disease, only those with 1 single nodal station ≤3 cm are eligible (only valid for Cohort 1).

    At screening, complete surgical resection of the primary NSCLC must be deemed achievable, as assessed by a multidisciplinary evaluation, which must include a thoracic surgeon who performs lung cancer surgery as a prominent part of his/her practice.

    • T4 tumors will only be eligible if they are defined as T4 based only on their size (more than 7 cm); any other reason for T4 (e.g., adherent to any of the following structures: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina) will be considered ineligible.
    • Nodal status should be investigated with whole-body fluorodeoxyglucose-positron emission tomography (FDG-PET), plus contrast-enhanced CT. If PET/CT scan is positive in the mediastinum, or if the scan is negative but there is T >3 cm, central tumor, or cN1, then it is recommended that nodal status be proven by via endobronchial ultrasound, mediastinoscopy, or thoracoscopy.
  5. (WHO PS) score or Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 at enrollment.
  6. Adequate organ and marrow function as defined below:

    • ≥9.0 g/dL.
    • (ANC) ≥1.5 × 109/L.
    • count ≥100 × 109/L.
    • Serum ≤1.5 × (ULN). This will not apply to patients with confirmed Gilbert's syndrome, who will be allowed upon consultation with their physician.
    • (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN.
    • Measured (CrCL) >40 mL/min or calculated CrCL >40 mL/min as determined by Cockcroft-Gault formula using actual body weight (Cockroft-Gault, 1976) (https://www.kidney.org/professionals/KDOQI/gfr_calculatorCoc).
  7. Must have a of at least 12 weeks.
  8. Body weight >35 kg.
  9. Male or female. Women of should use an acceptable method of from the time of screening throughout the total duration of the study, and (for drugs that are potentially genotoxic) the drug (180 days after the last dose of study drugs) to prevent pregnancy.

    A non-sterilized male partner of a woman of childbearing potential must use a male condom plus spermicide (or condom alone in countries where spermicides are not approved) throughout this period. Male patients who intend to be sexually active with a female partner of childbearing potential must be surgically sterile or using an acceptable method of contraception (from the time of screening throughout the total duration of the study and (for drugs that are potentially genotoxic) the drug washout period (180 days after the last dose of study drugs) to prevent pregnancy in a partner. Male patients must not donate or bank sperm during this same time period. For more details on contraceptive guidance of the study for both women of childbearing potential and non sterilized male patients.

  10. Negative pregnancy test (serum or urine) for women of childbearing potential.
  11. Provision of tumor samples (newly acquired [preferred] or archival tumor tissue [≤6 months old]) to confirm status, epidermal growth factor receptor (EGFR), or anaplastic lymphoma kinase (ALK) status, where required during screening and prior to nC1D1.

    (a) PD-L1 status: (i) If the patient's PD-L1 status has already been assessed using the analytically validated Ventana PD-L1 (SP263) immunohistochemistry (IHC) assay, 22C3 PharmDx assay, or 28-8 PharmDx assay, this test result can be used. (ii) Local laboratory results can be used if performed using the analytically validated Ventana PD-L1 (SP263) IHC assay, 22C3 PharmDx assay, or 28-8 PharmDx assay (iii) If appropriate local testing and/or previous results are not available, PD-L1 testing using the Ventana PD-L1 (SP263) IHC assay will be performed centrally using either newly acquired tumor tissue (preferred) or archival tissue (≤6 months old). Note: For Cohort 2 (PD-L1-positive cohort), only patients with PD-L1 expression tumor proportion score (TPS) ≥1% will be enrolled. (b) ALK and EGFR status: (i) Local laboratory results for ALK and EGFR will be obtained using a well validated, local-regulatory-approved assay. Neither patients with EGFR/ALK mutations nor those with unknown EGFR/ALK status will be enrolled, with the following exceptions:

    • Patients with documented Kirsten rat sarcoma virus (KRAS) mutations do not require EGFR/ALK status.
    • Patients with squamous cell carcinoma do not require ALK status.
  12. Provision of tumor samples appropriate for exploratory biomarker analyses
  13. Patients are suitable for inclusion if the planned surgery is lobectomy, sleeve resection, or bilobectomy, as determined by the attending surgeon based on the baseline findings. Patients whose planned surgery at enrollment includes pneumonectomy, segmentectomies, or wedge resections are not eligible for this study.
  14. A pre- or post-bronchodilator (FEV1) of 1.0 L and diffusing capacity of lung for carbon monoxide (DLCO) >40% postoperative predicted value. Use of these cut-off values to assess candidacy for resection should be guided by the results of cardiopulmonary exercise testing as outlined in the European Society for Medical Oncology (ESMO) guidelines on pre-treatment risk assessment. Both an FEV1 and a DLCO test are required for assessing lung function at screening.

Exclusion criteria

Exclusion Criteria

Patients meeting any of the following exclusion criteria will not be eligible to participate in the study:

  1. Patients with sensitizing EGFR mutations or ALK translocations.
  2. History of allogeneic organ transplantation.
  3. Active or prior documented or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, sarcoidosis syndrome, or Wegener syndrome [e.g., granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, or uveitis]). The following are exceptions to this criterion:

    • Patients with vitiligo or alopecia.
    • Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement.
    • Any chronic skin condition that does not require systemic therapy.
    • Patients without active disease in the last 5 years may be included but only after consultation with the Study Physician/Medical Scientist.
    • Patients with celiac disease controlled by diet alone.
  4. Uncontrolled intercurrent illness, including but not limited to, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active interstitial lung disease (ILD), serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs, or compromise the ability of the patient to give written .
  5. History of any grade of venous or arterial thromboembolic events including cerebrovascular accident, , or unstable angina pectoris within 6 months prior to enrollment.
  6. History of another primary , except for the following:

    • Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of study drugs and of low potential risk for recurrence.
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    • Adequately treated carcinoma in-situ without evidence of disease.
  7. Patients with small-cell lung cancer or mixed small-cell lung cancer.
  8. History of active primary immunodeficiency.
  9. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), (known positive hepatitis B surface antigen [HBsAg] result) and virus (HCV). Patients with a past or resolved hepatitis B virus (HBV) infection (defined as the presence of hepatitis B core antibody and absence of HBsAg) are eligible. Patients positive for HCV antibody are eligible only if the polymerase chain reaction test is negative for HCV RNA.
  10. Patients who have preoperative radiotherapy treatment as part of their care plan.
  11. Patients who require or may require pneumonectomy, segmentectomies, or wedge resections, as assessed by their surgeon, to obtain potentially curative resection of primary tumor.
  12. ≥470 ms (Note: If prolonged, then 2 additional [ECGs] should be obtained and the average QTcF interval should be used to determine eligibility).
  13. Known allergy or to any of the study drugs or any of the study drug .
  14. Any medical to treatment with chemotherapy as listed in the local labelling.
  15. Patients with moderate or severe cardiovascular disease:

    • Presence of cardiac disease, including myocardial infarction or unstable angina pectoris within 6 months prior to study entry.
    • (NYHA) Class III or IV congestive heart failure, or uncontrolled hypertension.
    • History of hypertensive crisis/hypertensive encephalopathy within 6 months prior to the scheduled first dose of study drugs.
  16. Any concurrent chemotherapy, product, biologic or hormonal therapy for cancer treatment. However, concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.
  17. Receipt of within 30 days prior to the first dose of study drugs. Note: If enrolled, patients should not be administered live vaccine while receiving study drugs and up to 30 days after the last dose of study drugs.
  18. Major surgical procedure (as defined by the Investigator) within 30 days prior to the first dose of study drugs.
  19. Prior exposure to immune-mediated therapy including, but not limited to, other , anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies. Patients who received agents targeting the adenosine pathway (e.g., anti-CD73 antibody, adenosine A2A receptor [A2AR] inhibitor, anti-CD39 antibody) are also excluded.
  20. Current or prior use of medication within 14 days before the first dose of study drugs. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical , or local steroid injections (e.g., intra-articular injection)
    • Systemic corticosteroids ≤12 mg/day of prednisone or its equivalent
    • Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
  21. Participation in another clinical study with an investigational product administered within 30 days prior to enrollment.
  22. Previous study drugs (durvalumab, IPH5201) assignment in the present study. Other Exclusions
  23. Female patients who are pregnant or breastfeeding, or male or female patients of who are not willing to employ effective from screening to 180 days after the last dose of study drugs administration.
  24. Involvement in the planning and/or conduct of the study (applies to both company staff and/or staff at the study site).
  25. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  26. Exclusion criteria for participation in the optional (DNA) genetics research component of the study include the following:

    • Previous bone marrow transplant
    • Non-leukocyte-depleted whole blood transfusion within 120 days before genetic sample collection.
  27. Only for patients in Cohort 2: Patients with PD-L1 expression TPS \<1% or unknown PD-L1 status.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    IPH5201 + durvalumab + standard chemotherapy

    Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy. In Cohort 1 only, following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab.

    Drug: IPH5201 + durvalumab + standard chemotherapy

Interventions

  • DrugIPH5201 + durvalumab + standard chemotherapy

    Drug page: Durvalumab

    Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy. In Cohort 1 only, Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab.

    Also known as: Durvalumab, MEDI4736, IMFINZI, Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy, Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy, Pemetrexed/Carboplatin Pemetrexed/Carboplatin as chemotherapy

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response (pCR)

    Number of patients with pathological Complete Response (pCR)

    Time frame: 16 weeks after the first dose of study intervention.

  2. Adverse events (AEs) and serious adverse events (SAEs)

    Number of patients with adverse events (AEs) and serious adverse events (SAEs).

    Time frame: Until Day 90 after the last dose of study interventions.

Secondary outcomes

  1. Event-Free Survival (EFS)

    Number of patients experiencing an Event-Free Survival (EFS) event.

    Time frame: Up to approximately 2 years.

  2. Disease Free Survival (DFS)

    Number of patients experiencing a Disease Free Survival (DFS) event (event from surgery onwards).

    Time frame: Up to approximately 2 years.

  3. Surgical resection

    Number of participants having surgical resection.

    Time frame: Approximately 16 weeks after the first dose of study intervention.

  4. Major Pathological Response (mPR)

    Number of patients with a major Pathological Response (mPR).

    Time frame: Approximately 16 weeks after the first dose of study intervention.

  5. Objective Response Rate (ORR)

    Number of patients with an Objective Response Rate (ORR).

    Time frame: Up to approximately 4 months adjuvant.

  6. Overall Survival (OS)

    Overall Survival (OS).

    Time frame: Up to approximately 2 years.

  7. PK of IPH5201 in combination with durvalumab +/- chemotherapy

    Serum concentration (PK) of IPH5201 in combination with durvalumab +/- chemotherapy, in patients receiving neoadjuvant and adjuvant treatment.

    Time frame: Up to approximately 4 months adjuvant.

  8. Anti-study drug antibodies (ADA)

    Number of patients with anti-study drug antibodies (ADA).

    Time frame: Up to approximately 4 months adjuvant.

07

Study locations

10 of 30 sites recruiting
  • St. Anthony's Hospital - BayCare Health System
    St. Petersburg, Florida 33705, United States
    Terminated

    Not enrolling at this site — choose another above.

  • H. Lee Moffitt Cancer Center & Research Institute
    Tampa, Florida 33612, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Northwell Health Cancer Institute / Center for Novel Cancer Therapeutics
    Lake Success, New York 11042, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Millennium Research & Clinical Development
    Houston, Texas 77090, United States
    Terminated

    Not enrolling at this site — choose another above.

  • UW Carbone Cancer Center - Cancer Connect
    Madison, Wisconsin 53792, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Angers University Hospital Center
    Angers, 49333, France
    Terminated

    Not enrolling at this site — choose another above.

  • University Hospital Center Caen
    Caen, 14033, France
    Terminated

    Not enrolling at this site — choose another above.

  • Hospital Calmette
    Lille, 59037, France
    Not yet recruiting
    • Alexis Cortot · Contact
  • CHU de Limoges
    Limoges, 87042, France
    Recruiting
    • Thomas Egenod · Contact
  • Leon Berard Center
    Lyon, 69373, France
    Recruiting
    • Maurice Perol · Contact
  • Marseille University Hospital Center - North Hospital
    Marseille, 13015, France
    Recruiting
    • Laurent Greillier · Contact
  • Rennes University Hospital Center - Hospital Pontchaillou
    Rennes, 35033, France
    Recruiting
    • Herve Lena · Contact
  • Charles Nicolle Hospital
    Rouen, 76031, France
    Terminated

    Not enrolling at this site — choose another above.

  • Gustave Roussy
    Villejuif, 94805, France
    Recruiting
    • Fabrice Barlesi · Contact
  • Henry Dunant Hospital Center
    Athens, 11526, Greece
    Withdrawn

    Not enrolling at this site — choose another above.

  • University General Hospital "Attikon"
    Athens, 12462, Greece
    Recruiting
    • Amanda Psyrri · Contact
  • University General Hospital of Ioannina
    Ioannina, 45500, Greece
    Terminated

    Not enrolling at this site — choose another above.

  • University General Hospital of Patras
    Pátrai, 26504, Greece
    Terminated

    Not enrolling at this site — choose another above.

  • Koranyi National Institute of Pulmonology, 14th Department of Pulmonology
    Budapest, H-1121, Hungary
    Recruiting
    • Gabriella Temesi · Contact
  • Veszprem County Pulmonology Institute
    Farkasgyepű, 8582, Hungary
    Terminated

    Not enrolling at this site — choose another above.

  • Petz Aladar University Teaching Hospital, Department of Pulmonology
    Győr, 9024, Hungary
    Terminated

    Not enrolling at this site — choose another above.

  • Jasz-Nagykun-Szolnok County Hetenyi Geza Hospital-Clinic, Department of Oncology
    Szolnok, H-5000, Hungary
    Recruiting
    • Lengyel · Contact
  • Pulmonology Institute Torokbalint
    Törökbálint, H-2045, Hungary
    Not yet recruiting
    • Gabriella Galffy · Contact
  • University Teaching Hospital in Bialystok, 2nd Department of Lung Diseases and Tuberculosis
    Bialystok, 15-540, Poland
    Recruiting
    • Robert Mroz · Contact
  • John Paul II Specialist Hospital in Krakow
    Krąków, 31-202, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Mandziuk Slawomir - Specialist Medical Practice
    Lublin, 20-093, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Eugenia and Janusz Zeyland Wielkopolskie Centre of Pulmonology and Thoracic Surgery
    Poznan, 60-569, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Specialist Hospital in Prabuty Sp. z o.o. (LLC)
    Prabuty, 82-550, Poland
    Recruiting
    • Anna Lowczak · Contact
  • Military Institute of Medicine - National Research Institute
    Warsaw, 04-141, Poland
    Terminated

    Not enrolling at this site — choose another above.

08

References and documents

Publications

  • https://aacrjournals.org/cancerres/article/86/8_Supplement/CT231/783296/Abstract-CT231-Dual-CD39-and-PD-L1-inhibition
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jun 2027, 48 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 48 months is above that.

Counting every sponsor, half of 1,046 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2023
First posted
Feb 24, 2023
StartActual
Jun 23, 2023
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05742607
Lead sponsor
Innate Pharma
Responsible party
Sponsor
First posted
Feb 24, 2023
Start date
Jun 23, 2023
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jun 17, 2026

Study contacts

Innate Pharma
Contact
clinical.trials@innate-pharma.fr
+33484903084

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion